시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 푹스각막내피이상증(FECD) 시장 보고서(2025년)
Fuchs Endothelial Corneal Dystrophy Global Market Report 2025
상품코드 : 1764321
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

푹스각막내피이상증 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 시장 성장은 특수 안과 분야의 확대, 질병의 유전적 및 분자적 메커니즘에 관한 연구의 진전에 의해 견인될 것으로 예측됩니다. 이 기간에 예상되는 주요 동향에는 재생 의료의 진보, 진단 프로세스와 인공지능의 통합, 생체 공학 각막 이식편의 기술 혁신, 수술 기술의 개선, 각막 이미징 시스템 내 첨단 기술의 채용 등이 있습니다.

각막 이식에 대한 수요 증가는 향후 몇 년간의 푹스각막내피이상증(FECD) 시장의 성장을 가속할 것으로 예측됩니다. 이상 조직을 기증자의 조직과 교환하여 시력과 적절한 안구 기능을 회복시킬 수 있습니다. FECD는 각막 내피를 서서히 손상하고 결국 시력을 손상시키므로 수술 개입을 필요로 하고 따라서 수요에 크게 기여하고 있습니다. 2023년, 미국 안구은행은 국내 각막이식술 증례가 7% 증가하여 2022년 4만 9,597건에서 2023년에는 5만 925건으로 증가했다고 보고하였습니다.

푹스각막내피이상증(FECD) 시장의 주요 기업은 각막 세포의 재생을 촉진하고 시력을 회복시키는 것을 목표로 Rho 키나아제 억제제와 같은 혁신적인 치료제를 개발하기 위해 임상 시험을 선호합니다. Rho 키나아제 억제제는 Rho 키나아제 경로를 억제함으로써 세포 스트레스를 경감하고 각막 내피 세포의 재생을 촉진하는 기능이 있으며, FECD의 유망한 치료 옵션으로 부상하고 있습니다. 2023년 4월에는 탈수막 수술 후 FECD 환자를 대상으로 K-321(리파스딜 염산염 2 수화물) 점안액의 안전성과 효능을 평가하는 국제 공동 제3상 임상 시험이 개시되었으며 본 시험은 많은 FECD 환자의 비외과적 치료법을 확립하는 것을 목표로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 팬데믹과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Fuchs endothelial corneal dystrophy (FECD) is a progressive eye condition that affects the endothelium, the innermost layer of the cornea. It involves the gradual degeneration of endothelial cells, which are critical for keeping the cornea clear by removing excess fluid. As these cells are lost, fluid accumulates in the cornea, leading to swelling, blurred vision, and, in more severe cases, pain.

Primary treatment options for FECD include phototherapeutic keratectomy, amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps. Phototherapeutic keratectomy (PTK) is a laser-based surgical technique used to remove surface-level corneal irregularities or opacities, helping to restore vision and alleviate discomfort associated with corneal diseases. Diagnosis commonly involves corneal examinations and grading, corneal tomography, pachymetry, and endothelial cell counts, among other methods. Treatments may be administered via oral, topical, or other routes and are delivered in a range of healthcare settings, including hospitals, specialty clinics, homecare, and others.

The fuchs endothelial corneal dystrophy market research report is one of a series of new reports from The Business Research Company that cover fuchs endothelial corneal dystrophy market statistics, including the fuchs endothelial corneal dystrophy industry's global market size, regional shares, competitors with the fuchs endothelial corneal dystrophy market share, detailed fuchs endothelial corneal dystrophy market segments, market trends and opportunities, and any further data you may need to thrive in the fuchs endothelial corneal dystrophy market. This fuchs endothelial corneal dystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fuchs endothelial corneal dystrophy market size has grown strongly in recent years. It will grow from $171.48 billion in 2024 to $185.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. Growth during the historic period can be attributed to the rising prevalence of age-related eye disorders, increasing demand for corneal transplants, improved awareness and diagnosis rates, greater adoption of minimally invasive surgical procedures, and growing investments in regenerative medicine.

The fuchs endothelial corneal dystrophy market size is expected to see strong growth in the next few years. It will grow to $251.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. Growth in the forecast period is expected to be driven by the increasing availability of advanced diagnostic imaging, rising healthcare expenditure, higher incidence of diabetes and hypertension, expanding reach of specialty eye clinics, and advancing research into the genetic and molecular mechanisms of the disease. Key trends anticipated during this period include progress in regenerative medicine, integration of artificial intelligence in diagnostic processes, innovations in bioengineered corneal grafts, improvements in surgical techniques, and the adoption of advanced technologies in corneal imaging systems.

The rising demand for corneal transplants is expected to drive the growth of the fuchs endothelial corneal dystrophy (FECD) market in the coming years. Corneal transplants involve replacing a damaged or diseased cornea with healthy donor tissue to restore vision and proper eye function. This demand is increasing due to the growing prevalence of corneal disorders that lead to vision loss and require surgical correction. FECD contributes significantly to this demand by progressively damaging the corneal endothelium, ultimately impairing vision and necessitating surgical intervention. For example, in 2023, the Eye Bank Association of America reported a 2.7% increase in domestic keratoplasty procedures, rising from 49,597 in 2022 to 50,925 in 2023. Thus, the growing need for corneal transplants is fueling the expansion of the FECD market.

Leading companies in the fuchs endothelial corneal dystrophy (FECD) market are prioritizing clinical trials to develop innovative treatments such as Rho kinase inhibitors, aimed at enhancing corneal cell regeneration and restoring vision. Rho kinase inhibitors work by blocking the Rho kinase pathway, which helps reduce cellular stress and promotes the regeneration of corneal endothelial cells, making them a promising therapeutic option for FECD. For example, in April 2023, Kowa Company, Ltd., a Japan-based pharmaceutical firm, initiated a global Phase 3 clinical trial to assess the safety and efficacy of K-321 (Ripasudil Hydrochloride Dihydrate) ophthalmic solution in patients with FECD following descemetorhexis. This trial seeks to establish a non-surgical treatment alternative for FECD, which often requires corneal transplantation in advanced stages. The study represents a significant step forward in expanding the use of Rho kinase inhibitors beyond glaucoma treatment and addressing the unmet clinical needs in FECD therapy.

In May 2022, Santen Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, entered into a partnership with ActualEyes Inc. to jointly develop and advance innovative therapeutic candidates for Fuchs endothelial corneal dystrophy. As part of this collaboration, they initiated the PHANTOM Phase IIa clinical trial. ActualEyes Inc., also based in Japan, is a biotechnology company focused on creating treatments for Fuchs endothelial corneal dystrophy.

Major players in the fuchs endothelial corneal dystrophy market are Carl Zeiss Meditec, Santen Pharmaceutical Co. Ltd., Design Therapeutics Inc., Stealth BioTherapeutics Corp., ProQR Therapeutics N.V., Surrozen Inc., Cellusion Inc., Price Vision Group LLC, ActualEyes Inc., Arctic Vision Limited, Aurion Biotech Inc., Emmecell Inc., Invirsa Inc., KeraMed Inc., Kowa Company Ltd., Kuria Therapeutics Inc., Massachusetts Eye and Ear, MediciBIO Co. LTD., Prime Medicine Inc., and Trefoil Therapeutics.

North America was the largest region in the fuchs endothelial corneal dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fuchs endothelial corneal dystrophy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fuchs endothelial corneal dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fuchs endothelial corneal dystrophy market includes revenues earned by entities by providing services such as diagnosis services, corneal pachymetry, specular microscopy, slit-lamp examination, and visual acuity testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The fuchs endothelial corneal dystrophy market also includes sales of artificial tears, hypertonic saline drops, ointments, bandage contact lenses, and endothelial keratoplasty kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fuchs Endothelial Corneal Dystrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fuchs endothelial corneal dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fuchs endothelial corneal dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fuchs endothelial corneal dystrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Subsegments

Table of Contents

1. Executive Summary

2. Fuchs Endothelial Corneal Dystrophy Market Characteristics

3. Fuchs Endothelial Corneal Dystrophy Market Trends And Strategies

4. Fuchs Endothelial Corneal Dystrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fuchs Endothelial Corneal Dystrophy Growth Analysis And Strategic Analysis Framework

6. Fuchs Endothelial Corneal Dystrophy Market Segmentation

7. Fuchs Endothelial Corneal Dystrophy Market Regional And Country Analysis

8. Asia-Pacific Fuchs Endothelial Corneal Dystrophy Market

9. China Fuchs Endothelial Corneal Dystrophy Market

10. India Fuchs Endothelial Corneal Dystrophy Market

11. Japan Fuchs Endothelial Corneal Dystrophy Market

12. Australia Fuchs Endothelial Corneal Dystrophy Market

13. Indonesia Fuchs Endothelial Corneal Dystrophy Market

14. South Korea Fuchs Endothelial Corneal Dystrophy Market

15. Western Europe Fuchs Endothelial Corneal Dystrophy Market

16. UK Fuchs Endothelial Corneal Dystrophy Market

17. Germany Fuchs Endothelial Corneal Dystrophy Market

18. France Fuchs Endothelial Corneal Dystrophy Market

19. Italy Fuchs Endothelial Corneal Dystrophy Market

20. Spain Fuchs Endothelial Corneal Dystrophy Market

21. Eastern Europe Fuchs Endothelial Corneal Dystrophy Market

22. Russia Fuchs Endothelial Corneal Dystrophy Market

23. North America Fuchs Endothelial Corneal Dystrophy Market

24. USA Fuchs Endothelial Corneal Dystrophy Market

25. Canada Fuchs Endothelial Corneal Dystrophy Market

26. South America Fuchs Endothelial Corneal Dystrophy Market

27. Brazil Fuchs Endothelial Corneal Dystrophy Market

28. Middle East Fuchs Endothelial Corneal Dystrophy Market

29. Africa Fuchs Endothelial Corneal Dystrophy Market

30. Fuchs Endothelial Corneal Dystrophy Market Competitive Landscape And Company Profiles

31. Fuchs Endothelial Corneal Dystrophy Market Other Major And Innovative Companies

32. Global Fuchs Endothelial Corneal Dystrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fuchs Endothelial Corneal Dystrophy Market

34. Recent Developments In The Fuchs Endothelial Corneal Dystrophy Market

35. Fuchs Endothelial Corneal Dystrophy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기